BST Trade Alert – January 29, 2015
Recommendation:
Buy Dyax (NASDAQ: DYAX) up to $16.50 per share.
About the Company:
DYAX is a biopharmaceutical company that develops drugs to treat Hereditary Angioedema (HAE) and Other Plasma-Kallikrein-Mediated Disorders.
And we believe DYAX has enormous potential.
They have one product, ecallantide, that’s already approved by the FDA for treatment of HAE in patients 12 years of age and older. It is marketed under the brand name KALBITOR.
They also have another product to treat HAE in development called DX-2930. It is currently in phase 1 testing.
DYAX also has a licensing and funded research portfolio with multiple revenue generating product candidates in clinical trials. These are products that licensees and collaborators bear the cost of development but DYAX stands to profit from if the treatments are approved.
Obviously, there’s a lot to like about DYAX.
But a good pipeline of drugs isn’t all that DYAX has to offer. They also have enough cash to last more than two years at their current burn rate.
About the Drug:
Hereditary angioedema (HAE) is a rare disease, characterized by localized swelling, inflammation, and pain.
KALBITOR, a potent, selective and reversible plasma kallikrein inhibitor, was the first subcutaneous HAE treatment approved in the United States and the only subcutaneous therapy available to treat attacks in patients 12 years of age and older.
DX-2930, a potent and specific fully human monoclonal antibody is an inhibitor of plasma kallikrein. DX-2930 is an investigational product candidate to treat HAE prophylactically and potentially other PKM disorders.
It has the potential for subcutaneous administration, with a half-life that could enable less frequent dosing than currently available prophylactic HAE therapies and an advantageous immunogenicity profile.
About the Market for This Drug:
It is estimated that HAE affects between 1 in 10,000 and 1 in 50,000 people worldwide. The U.S. Hereditary Angioedema Association estimates that there are approximately 6,500 HAE patients in the United States.
About the Potential Catalyst:
Right now, KALBITOR is only available in the US. But they are working to expand into markets outside of the US. Expectations for sales are rising as earnings estimates have risen over the last few months.
And the potential approval of KALBITOR outside the US is a bullish catalyst.
Another more important catalyst is the ongoing trial results of DX-2930 that are expected in the next few months.
About the Shares:
DYAX is currently trading for $15.44. It’s up 8.0% this year and up 78.0% over the last year.
We believe the strong performance will continue as sales grow and new trial results are received.
This is one biotech stock that has everything we’re looking for… a strong pipeline, a solid financial position, and bullish momentum.
Grab your shares of DYAX now to ride the wave of bullish momentum.
Key Facts:
Company: Dyax
Ticker: DYAX
Recent Price: $15.44
Market Cap: $2.07 billion
Average Daily Volume: 369.02K shares
Chart:
Category: BST Trade Alert
